The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis
Etewa, S., Al-Hoot, A., Abdelmoaty, S., Mohammad, S., Moawad, H., Sarhan, M., Abd El-Rahman, S., El-Shafey, M., Abd El-Monem, E. (2019). The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis. EKB Journal Management System, 12(1), 34-44. doi: 10.21608/puj.2019.7541.1030
Samia El-Sayed Etewa; Abd-Allah Al-Sayed Al-Hoot; Shimaa Mohamed Abdelmoaty; Samira Metwally Mohammad; Howayda Said Fouad Moawad; Mohamed Hassan Sarhan; Sara Ahmed Abd El-Rahman; Mahmoud Abd El-Aaty El-Shafey; Eman Zakaria Abd El-Monem. "The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis". EKB Journal Management System, 12, 1, 2019, 34-44. doi: 10.21608/puj.2019.7541.1030
Etewa, S., Al-Hoot, A., Abdelmoaty, S., Mohammad, S., Moawad, H., Sarhan, M., Abd El-Rahman, S., El-Shafey, M., Abd El-Monem, E. (2019). 'The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis', EKB Journal Management System, 12(1), pp. 34-44. doi: 10.21608/puj.2019.7541.1030
Etewa, S., Al-Hoot, A., Abdelmoaty, S., Mohammad, S., Moawad, H., Sarhan, M., Abd El-Rahman, S., El-Shafey, M., Abd El-Monem, E. The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis. EKB Journal Management System, 2019; 12(1): 34-44. doi: 10.21608/puj.2019.7541.1030

The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis

Parasitologists United Journal
Article 6, Volume 12, Issue 1, April 2019, Page 34-44  XML PDF (547.1 K)
Document Type: Original Article
DOI: 10.21608/puj.2019.7541.1030
View on SCiNiTO View on SCiNiTO
Authors
Samia El-Sayed Etewa1; Abd-Allah Al-Sayed Al-Hoot2; Shimaa Mohamed Abdelmoaty2; Samira Metwally Mohammad1; Howayda Said Fouad Moawadorcid 1; Mohamed Hassan Sarhan email orcid 1; Sara Ahmed Abd El-Rahman1; Mahmoud Abd El-Aaty El-Shafey3; Eman Zakaria Abd El-Monem2
1Medical Parasitology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt
2Zoology Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt
3Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt
Abstract
Background: Toxoplasmosis is considered of the widest spread parasitic infections that affects approximately one third of human population. The formation of resident tissue cysts in chronically infected hosts is a challenge; none of the available drugs is capable of eradicating encysted forms of the parasite. It could be disastrous in immunosuppression due to reactivation of the dormant infection. The application of stem cells as promising therapy was tried in some parasitic diseases.
Objective: In this work, stem cells therapy was investigated as a therapeutic line in treatment of murine toxoplasmosis.
Materials and Methods: Parasitological, histopathological and immunohistochemical studies were performed to investigate the curable role of Bone Marrow Mesenchymal Stem Cells (BM MSCs).
Results: The outcomes revealed high significant decrease of the number and size of brain tissue cysts on combining BM MSCs with spiramycin, pyrimethamine and folinic acid. The tested group by BM MSCs as mono-theraputic line of treatment showed poor curable role, as cleared by the results of liver, spleen, eye and brain tissues studies; some improvement was noticed by the recruitment of CD8+ that was cleared by the immunohistochemical study of brain and spleen sections.
Conclusion: BM MSCs alone have a poor therapeutic role, otherwise combined with spiramycin, pyrimethamine and folinic acid for treatment of toxoplasmosis.
Keywords
Bone marrow mesenchymal stem cells; immunosuppression; Pyrimethamine, MSCs; Spiramycin; Toxoplasmosis
Statistics
Article View: 427
PDF Download: 511